Johnson & Johnson to Initiate P-I/IIa Clinical Study of its COVID-19 Vaccine in July

Shots:

Janssen has accelerated the initiation of the P-I/IIa study of its investigational Ad26.COV2-S recombinant vaccine. Earlier, the company had scheduled the clinical trial to begin in Sept’2020, the trial is now expected to commence in the second half of July
The P-I/IIa study will evaluate the safety, reactogenicity & immunogenicity Ad26.COV2-S, recombinant in 1045 adults aged 18-55 yrs. as well as adults aged 65+yrs. The study will conduct the US and Belgium
Janssen is in discussion with NIAID intending to initiate P-III study for Ad26.COV2-S, recombinant depending on results of the P-I studies and regulatory approval. The Company focuses on supplying 1B+ doses globally through the course of 2021, provided the vaccine is safe and effective

Click here to read full press release/ article | Ref: Johnson & Johnson | Image: YouTube